Physician profile
Imelda Lim
NPI 1093130395
$1,426.59
in general payments reported to CMS, 2019-2025
15 companies · $94.94 in 2025
The $94.94 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $321 · 2022: $247 · 2023: $495 · 2024: $268 · 2025: $94.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $462.55 | 2021-2024 | Wegovy |
| Medtronic, INC. | $205.89 | 2022-2023 | Micra, Linq II |
| Abbott Laboratories | $147.67 | 2023 | Gallant |
| Kestra Medical Technology Services, INC. | $109.89 | 2024 | Assure Wcd |
| Gilead Sciences, INC. | $94.81 | 2022 | |
| Amgen INC. | $73.38 | 2023-2024 | Otezla, Repatha |
| Hologic Sales and Service, LLC | $68.69 | 2024-2025 | Aptima |
| Exact Sciences Corporation | $58.33 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $54.56 | 2024-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $42.91 | 2024 | |
| Xeris Pharmaceuticals, INC. | $23.98 | 2023 | Gvoke Hypopen |
| Astellas Pharma US INC | $22.98 | 2024 | Veozah |
| Dexcom, INC. | $22.87 | 2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $19.26 | 2023 | |
| Esperion Therapeutics, INC. | $18.82 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imelda Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.